MX2024003275A - Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas. - Google Patents
Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas.Info
- Publication number
- MX2024003275A MX2024003275A MX2024003275A MX2024003275A MX2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A MX 2024003275 A MX2024003275 A MX 2024003275A
- Authority
- MX
- Mexico
- Prior art keywords
- fusion proteins
- methods
- polypeptides
- polypeptide
- caix targeting
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/522—CH1 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245523P | 2021-09-17 | 2021-09-17 | |
| PCT/US2022/043762 WO2023043978A2 (en) | 2021-09-17 | 2022-09-16 | Caix targeting il-12 fusion proteins and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003275A true MX2024003275A (es) | 2024-05-07 |
Family
ID=85603506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003275A MX2024003275A (es) | 2021-09-17 | 2022-09-16 | Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240392031A1 (https=) |
| EP (1) | EP4402158A4 (https=) |
| JP (1) | JP2024534468A (https=) |
| KR (1) | KR20240161081A (https=) |
| CN (1) | CN118369331A (https=) |
| AU (1) | AU2022345103A1 (https=) |
| CA (1) | CA3232632A1 (https=) |
| IL (1) | IL311442A (https=) |
| MX (1) | MX2024003275A (https=) |
| WO (1) | WO2023043978A2 (https=) |
| ZA (1) | ZA202402034B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI880235B (zh) | 2017-11-28 | 2025-04-11 | 日商中外製藥股份有限公司 | 可調整配體結合活性的配體結合分子 |
| WO2025012105A2 (en) * | 2023-07-07 | 2025-01-16 | Technische Universitaet Muenchen, In Vertretung Des Freistaates Bayern | Muteins of human interleukin 12 |
| WO2025101133A1 (en) * | 2023-11-10 | 2025-05-15 | Agency For Science, Technology And Research | Interleukin-12 variants and medical uses thereof |
| WO2025136986A2 (en) | 2023-12-18 | 2025-06-26 | Genzyme Corporation | Il-12 loss of potency muteins |
| WO2025205534A1 (ja) * | 2024-03-25 | 2025-10-02 | 積水メディカル株式会社 | 免疫測定方法、精度管理方法、標準試料及び免疫測定試薬 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1966238T3 (pl) * | 2005-12-30 | 2012-09-28 | Merck Patent Gmbh | Warianty interleukiny-12p40 o polepszonej stabilności |
| US20210130430A1 (en) * | 2018-05-14 | 2021-05-06 | Werewolf Therapeutics, Inc. | Activatable cytokine polypeptides and methods of use thereof |
| CN115916261A (zh) * | 2020-04-17 | 2023-04-04 | 小利兰·斯坦福大学董事会 | 工程化il-12和il-23多肽及其用途 |
-
2022
- 2022-09-16 EP EP22870726.1A patent/EP4402158A4/en active Pending
- 2022-09-16 CA CA3232632A patent/CA3232632A1/en active Pending
- 2022-09-16 IL IL311442A patent/IL311442A/en unknown
- 2022-09-16 AU AU2022345103A patent/AU2022345103A1/en active Pending
- 2022-09-16 JP JP2024517044A patent/JP2024534468A/ja active Pending
- 2022-09-16 KR KR1020247012576A patent/KR20240161081A/ko active Pending
- 2022-09-16 WO PCT/US2022/043762 patent/WO2023043978A2/en not_active Ceased
- 2022-09-16 MX MX2024003275A patent/MX2024003275A/es unknown
- 2022-09-16 CN CN202280076070.8A patent/CN118369331A/zh active Pending
-
2024
- 2024-03-12 ZA ZA2024/02034A patent/ZA202402034B/en unknown
- 2024-03-15 US US18/607,049 patent/US20240392031A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4402158A2 (en) | 2024-07-24 |
| ZA202402034B (en) | 2025-06-25 |
| WO2023043978A2 (en) | 2023-03-23 |
| CA3232632A1 (en) | 2023-03-23 |
| EP4402158A4 (en) | 2025-07-30 |
| CN118369331A (zh) | 2024-07-19 |
| JP2024534468A (ja) | 2024-09-20 |
| KR20240161081A (ko) | 2024-11-12 |
| US20240392031A1 (en) | 2024-11-28 |
| AU2022345103A1 (en) | 2024-03-28 |
| WO2023043978A3 (en) | 2023-09-28 |
| IL311442A (en) | 2024-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024003275A (es) | Caix dirigido a proteínas de fusión de il-12 y métodos de uso de las mismas. | |
| CL2022000300A1 (es) | Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252) | |
| CL2021002241A1 (es) | Proteínas de unión condicionalmente activadas restringidas (divisional de la solicitud no. 202000570) | |
| BR112022000371A2 (pt) | Anticorpos claudin18 e métodos de tratamento contra câncer | |
| CL2023003607A1 (es) | Anticuerpos anti-ccr8 y usos de los mismos | |
| CY1125392T1 (el) | Συνθεσεις και μεθοδοι γλυζυλιωσης πρωτεϊνων | |
| MX2019004692A (es) | Anticuerpos 4-1bb anti-humano y usos de los mismos. | |
| PE20241994A1 (es) | Proteina mutante de interleucina-2 y fusion de la misma | |
| CY1122391T1 (el) | Pan-kir2dl nk-υποδοχεα αντισωματα και χρηση αυτων σε διαγνωστικη και θεραπεια | |
| PE20251254A1 (es) | Proteinas de anticuerpo injertadas con citocina y metodos de uso en el tratamiento del cancer | |
| BR112021018608A2 (pt) | Anticorpos para claudina-6 e conjugados de fármaco | |
| CL2018000358A1 (es) | Proteínas de fusión de gitrl y usos de las mismas | |
| ECSP077888A (es) | Anticuerpos anti-il-6, composiciones, metodos y usos | |
| MX2020002921A (es) | Anticuerpos para claudin6 y métodos para tratar el cáncer. | |
| MX2021007235A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
| BR112018073221A2 (pt) | métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina | |
| CO2024013569A2 (es) | Moléculas de unión contra frα | |
| MX2022015769A (es) | Tubulisinas y conjugados de proteina-tubulisina. | |
| MX2021009851A (es) | Formulacion de anticuerpos terapeuticos. | |
| CO2023002375A2 (es) | Anticuerpos contra ilt2 y uso de los mismos | |
| MX2021002225A (es) | Composiciones y metodos para la reprogramacion de tcr mediante el uso de proteinas de fusion. | |
| AR060104A1 (es) | Modulacion de la formacion de huesos | |
| CL2021002188A1 (es) | Moléculas biespecíficas de unión al antígeno y métodos de uso. | |
| MX2022006784A (es) | Formulaciones de anticuerpos anti-pd-l1. | |
| CO2025007355A2 (es) | Anticuerpo anti-trem2 y usos del mismo |